Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.
about
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and childrenNeuraminidase inhibitors for preventing and treating influenza in healthy adultsNeuraminidase inhibitors for preventing and treating influenza in healthy adultsInfluenza neuraminidase inhibitors: antiviral action and mechanisms of resistanceChemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tractZanamivir: from drug design to the clinicPermeability enhancers dramatically increase zanamivir absolute bioavailability in rats: implications for an orally bioavailable influenza treatmentDetection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in JapanCarrier-Mediated Prodrug Uptake to Improve the Oral Bioavailability of Polar Drugs: An Application to an Oseltamivir AnalogueThe pharmacological management of severe influenza infection - 'existing and emerging therapies'.Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II studyFrom neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.Antiviral strategies for pandemic and seasonal influenzaPandemic 2009 H1N1 influenza A virus carrying a Q136K mutation in the neuraminidase gene is resistant to zanamivir but exhibits reduced fitness in the guinea pig transmission model.Neuraminidase inhibitors: zanamivir and oseltamivir.Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061.Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in miceDirect measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalationDeveloping new antiviral agents for influenza treatment: what does the future hold?Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical modelAn open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults.Spotlight on zanamivir in influenza.Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach.Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCSAlterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever.Development of oseltamivir phosphonate congeners as anti-influenza agentsClinical review: update of avian influenza A infections in humans.Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairmentSafety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women.Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility.CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.Mechanistic enhancement of the intestinal absorption of drugs containing the polar guanidino functionality.Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach.Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.Antiviral strategies against influenza virus: towards new therapeutic approaches.Optimizing antiviral therapy for influenza: understanding the evidence.Clinical pharmacokinetics of inhaled antimicrobials.Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects.Zanamivir: an influenza virus neuraminidase inhibitor.
P2860
Q24203905-080F3AF1-9732-4A79-B1BA-46E0D5CD9834Q24240097-74E5795A-1AF9-49D0-B017-858BE8A28052Q24244898-73BDF1F8-AA4F-49ED-9B21-7427CE9C3DF3Q28282405-28E8287D-7938-45C6-ACD1-94FB6EAC1A7CQ28343667-AB60C1B4-43CC-42CF-87E1-58F3EECB6966Q28344586-BFF5E86F-F56A-43F2-AE38-71FBFF6D4C90Q28486267-7D733B2D-FBA1-435B-8BA0-56C3B1667D17Q28545776-9E5E7827-B090-4F73-938A-1EE5F52359E2Q28833485-488FFF54-54B2-4A29-B524-8D47C043CC27Q30243907-0F297E6E-3E3F-4740-9AC1-64C4B7EE99DFQ30353217-27289D95-605B-41C6-A525-DAA439B9712BQ30363724-4325353D-6C6A-41A0-A90F-7CD9AC78ED8AQ30404586-EA97782C-86D2-461E-8B54-FC19BC412C46Q30408116-BEEE3EE5-C593-49CF-9160-F4BCFC13E9FFQ30424185-ED85394F-CE44-4EF8-962F-02A91D2AC7D6Q31989695-4BF23228-76E5-4554-8981-6469876D9190Q33456110-66DBAE40-9AC8-46CD-96E8-A81E7A49D55FQ33761451-EE65CDE3-3E40-493A-865E-E9C18496B054Q33980106-9B349752-E95B-41F5-A785-06C8058347DFQ34015113-8D99771B-5BED-46DD-85C5-84E03566E5D8Q34737693-B8A8C5E8-2F33-4C3F-AFEA-776165C4F46BQ35191600-BF47B4A7-4D06-4563-A9EF-078C336669C9Q35627901-31B1D375-0BEB-4541-AE18-0DA68842F532Q35831312-48146674-A142-489F-B540-FC23C947D819Q35952140-2F845C3D-556F-43CE-BBD4-8EC8D11C929FQ35952190-7073CD38-6224-4E8E-AEB6-82ABD7999205Q36382214-B4EAA7DC-9082-47E9-9C7F-D2B95C72494FQ36392514-6B358F31-FC29-4BFA-A348-0B8BFFF5917BQ36969884-09DE517E-5C1F-4039-AD63-6992BE63D196Q37247004-98C449B5-DF43-4660-9923-D649229E85CCQ37394266-95A37655-91AB-4BB6-A8B7-9F3B13F05776Q37409848-C5C8D68E-8F6D-4C6F-A324-88C4362BB2B4Q37828505-E06FCD11-1C4C-4A3B-8170-DC66A513B3F4Q38019048-1438E381-968B-49D2-B16D-FC2366CD194CQ38084212-B95E0E25-2478-4EF7-8715-7752A0172CADQ38202012-3D1554A1-08DB-415A-84AF-B7D0CB2B53BDQ38361244-4FCD3566-5A35-4C29-B3B1-819076CA258DQ38367260-BB2CA8EB-CF60-47CA-8A4F-F20F86A6E4EEQ38726043-4D5FA2C9-1B41-4880-B70A-6220D9372D76Q40419399-5850EF3E-E1B2-4E6E-8EDE-C0E9A391B3BB
P2860
Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Pharmacokinetics of zanamivir ...... tration to healthy volunteers.
@en
Pharmacokinetics of zanamivir ...... tration to healthy volunteers.
@nl
type
label
Pharmacokinetics of zanamivir ...... tration to healthy volunteers.
@en
Pharmacokinetics of zanamivir ...... tration to healthy volunteers.
@nl
prefLabel
Pharmacokinetics of zanamivir ...... tration to healthy volunteers.
@en
Pharmacokinetics of zanamivir ...... tration to healthy volunteers.
@nl
P2093
P1476
Pharmacokinetics of zanamivir ...... tration to healthy volunteers.
@en
P2093
P356
10.2165/00003088-199936001-00001
P478
36 Suppl 1
P577
1999-01-01T00:00:00Z
P6179
1047323674